Search

Your search keyword '"Cimmino, Giovanni"' showing total 29 results
Start Over Author "Cimmino, Giovanni" Publisher mdpi ag
29 results on '"Cimmino, Giovanni"'

3. An Unusual Case of a Double Tricuspid and Mitral Valves Infective Endocarditis Complicated by Multiple Septic Embolisms Secondary to an Atrial Septal Defect: A Case Report and Review of Literature

Author

Monari, Caterina, primary, Molinari, Daniele, additional, Cornelli, Alessandro, additional, Alessio, Loredana, additional, Coppolino, Francesco, additional, Barbareschi, Consiglia, additional, De Pascalis, Stefania, additional, Torella, Michele, additional, Cimmino, Giovanni, additional, De Feo, Marisa, additional, Coppola, Nicola, additional, and Formisano, Tiziana, additional

Published
2023
Full Text
View/download PDF

4. Non-Conventional Risk Factors: “Fact” or “Fake” in Cardiovascular Disease Prevention?

Author

Cimmino, Giovanni, primary, Natale, Francesco, additional, Alfieri, Roberta, additional, Cante, Luigi, additional, Covino, Simona, additional, Franzese, Rosa, additional, Limatola, Mirella, additional, Marotta, Luigi, additional, Molinari, Riccardo, additional, Mollo, Noemi, additional, Loffredo, Francesco S, additional, and Golino, Paolo, additional

Published
2023
Full Text
View/download PDF

5. Cardiovascular Effects of Weight Loss in Obese Patients with Diabetes: Is Bariatric Surgery the Additional Arrow in the Quiver?

Author

Bottino, Roberta, primary, Carbone, Andreina, additional, Formisano, Tiziana, additional, D’Elia, Saverio, additional, Orlandi, Massimiliano, additional, Sperlongano, Simona, additional, Molinari, Daniele, additional, Castaldo, Pasquale, additional, Palladino, Alberto, additional, Barbareschi, Consiglia, additional, Tolone, Salvatore, additional, Docimo, Ludovico, additional, and Cimmino, Giovanni, additional

Published
2023
Full Text
View/download PDF

7. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

Author

Nardone, Valerio, primary, Belfiore, Maria Paola, additional, De Chiara, Marco, additional, De Marco, Giuseppina, additional, Patanè, Vittorio, additional, Balestrucci, Giovanni, additional, Buono, Mauro, additional, Salvarezza, Maria, additional, Di Guida, Gaetano, additional, D’Angiolella, Domenico, additional, Grassi, Roberta, additional, D’Onofrio, Ida, additional, Cimmino, Giovanni, additional, Della Corte, Carminia Maria, additional, Gambardella, Antonio, additional, Morgillo, Floriana, additional, Ciardiello, Fortunato, additional, Reginelli, Alfonso, additional, and Cappabianca, Salvatore, additional

Published
2023
Full Text
View/download PDF

10. Current Views on Infective Endocarditis: Changing Epidemiology, Improving Diagnostic Tools and Centering the Patient for Up-to-Date Management

Author

Cimmino, Giovanni, primary, Bottino, Roberta, additional, Formisano, Tiziana, additional, Orlandi, Massimiliano, additional, Molinari, Daniele, additional, Sperlongano, Simona, additional, Castaldo, Pasquale, additional, D’Elia, Saverio, additional, Carbone, Andreina, additional, Palladino, Alberto, additional, Forte, Lavinia, additional, Coppolino, Francesco, additional, Torella, Michele, additional, and Coppola, Nicola, additional

Published
2023
Full Text
View/download PDF

12. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients

Author

Nardone, Valerio, primary, Reginelli, Alfonso, additional, De Marco, Giuseppina, additional, Natale, Giovanni, additional, Patanè, Vittorio, additional, De Chiara, Marco, additional, Buono, Mauro, additional, Russo, Gaetano Maria, additional, Monti, Riccardo, additional, Balestrucci, Giovanni, additional, Salvarezza, Maria, additional, Di Guida, Gaetano, additional, D’Ippolito, Emma, additional, Sangiovanni, Angelo, additional, Grassi, Roberta, additional, D’Onofrio, Ida, additional, Belfiore, Maria Paola, additional, Cimmino, Giovanni, additional, Della Corte, Carminia Maria, additional, Vicidomini, Giovanni, additional, Fiorelli, Alfonso, additional, Gambardella, Antonio, additional, Morgillo, Floriana, additional, and Cappabianca, Salvatore, additional

Published
2023
Full Text
View/download PDF

14. Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?

Author

Cimmino, Giovanni, primary, Conte, Stefano, additional, Morello, Mariarosaria, additional, Pellegrino, Grazia, additional, Marra, Laura, additional, Morello, Andrea, additional, Nicoletti, Giuseppe, additional, De Rosa, Gennaro, additional, Golino, Paolo, additional, and Cirillo, Plinio, additional

Published
2022
Full Text
View/download PDF

19. Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization

Author

Russo, Vincenzo, primary, Piccinocchi, Gaetano, additional, Mandaliti, Vincenzo, additional, Annunziata, Saverio, additional, Cimmino, Giovanni, additional, Attena, Emilio, additional, Moio, Nicola, additional, Di Micco, Pierpaolo, additional, Severino, Sergio, additional, Trotta, Roberta, additional, and Del Guercio, Michele, additional

Published
2020
Full Text
View/download PDF

20. The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome

Author

Radmilovic, Juri, primary, Di Vilio, Alessandro, additional, D’Andrea, Antonello, additional, Pastore, Fabio, additional, Forni, Alberto, additional, Desiderio, Alfonso, additional, Ragni, Massimo, additional, Quaranta, Gaetano, additional, Cimmino, Giovanni, additional, Russo, Vincenzo, additional, Scherillo, Marino, additional, and Golino, Paolo, additional

Published
2020
Full Text
View/download PDF

23. Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?

Author

Francesco Natale, Riccardo Molinari, Rosa Franzese, Noemi Mollo, Giovanni Cimmino, Natale, Francesco, Molinari, Riccardo, Franzese, Rosa, Mollo, Noemi, and Cimmino, Giovanni

Subjects
atherosclerosi, low-density lipoprotein, lipid-lowering strategy
Abstract

The goal in cardiovascular prevention is the reduction of morbidity and mortality through the promotion of healthy lifestyles in the general population. The management of modifiable risk factors with pharmacological and non-pharmacological interventions, based on the individual risk is the first strategy suggested by the current guidelines. Several epidemiological studies have clearly shown the direct correlation between high levels of low-density lipoprotein cholesterol (LDL-C) and incidence of cardiovascular diseases. On the other hand, numerous randomized clinical studies have reported a huge benefit in terms of major cardiovascular events achievable by the reduction of LDL-C, thus supporting the notion that “the lower is better”. Among the lipid-lowering strategies, statins are the drugs of choice in cardiovascular prevention, at both primary and secondary level. To achieve the ambitious targets suggested by the current guidelines, other lipid-lowering therapies are currently available in addition to statins, such as ezetimibe the inhibitors of the PCSK9. Pharmacological research has recently led to the development of a new drug, the bempedoic acid, which further enrich the available therapies. This drug also acts on the biosynthesis of cholesterol but at upstream level than statins. From the biochemical point of view, it has the potential to be considered before the statin with consequent titration of statins to achieve the desirable LDL-C target. In the present review, the biochemical and pharmacological characteristics of bempedoic acid are discussed. An overview of the clinical data that support its use in the management of the cardiovascular patient and its allocation in the lipid-lowering scenario will be also provided.

Published
2023
Full Text
View/download PDF

24. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

Author

Valerio Nardone, Maria Paola Belfiore, Marco De Chiara, Giuseppina De Marco, Vittorio Patanè, Giovanni Balestrucci, Mauro Buono, Maria Salvarezza, Gaetano Di Guida, Domenico D’Angiolella, Roberta Grassi, Ida D’Onofrio, Giovanni Cimmino, Carminia Maria Della Corte, Antonio Gambardella, Floriana Morgillo, Fortunato Ciardiello, Alfonso Reginelli, Salvatore Cappabianca, Nardone, Valerio, Belfiore, Maria Paola, DE CHIARA, Marco, DE MARCO, Giuseppina, Patanè, Vittorio, Balestrucci, Giovanni, Buono, Mauro, Salvarezza, Maria, Di Guida, Gaetano, D’Angiolella, Domenico, Grassi, Roberta, D’Onofrio, Ida, Cimmino, Giovanni, DELLA CORTE, Carminia Maria, Gambardella, Antonio, Morgillo, Floriana, Ciardiello, Fortunato, Reginelli, Alfonso, and Cappabianca, Salvatore

Subjects
thoracic imaging, Clinical Biochemistry, cardiac MRI, cardiac CT, NSCLC, radiotherapy
Abstract

Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.

Published
2023
Full Text
View/download PDF

25. Current Views on Infective Endocarditis: Changing Epidemiology, Improving Diagnostic Tools and Centering the Patient for Up-to-Date Management

Author

Giovanni Cimmino, Roberta Bottino, Tiziana Formisano, Massimiliano Orlandi, Daniele Molinari, Simona Sperlongano, Pasquale Castaldo, Saverio D’Elia, Andreina Carbone, Alberto Palladino, Lavinia Forte, Francesco Coppolino, Michele Torella, Nicola Coppola, Cimmino, Giovanni, Bottino, Roberta, Formisano, Tiziana, Orlandi, Massimiliano, Molinari, Daniele, Sperlongano, Simona, Castaldo, Pasquale, D'Elia, Saverio, Carbone, Andreina, Palladino, Alberto, Forte, Lavinia, Coppolino, Francesco, Torella, Michele, and Coppola, Nicola

Subjects
Space and Planetary Science, antibiotic, Paleontology, imaging technique, multidisciplinary team, infection, General Biochemistry, Genetics and Molecular Biology, Ecology, Evolution, Behavior and Systematics
Abstract

Infective endocarditis (IE) is a rare but potentially life-threatening disease, sometimes with longstanding sequels among surviving patients. The population at high risk of IE is represented by patients with underlying structural heart disease and/or intravascular prosthetic material. Taking into account the increasing number of intravascular and intracardiac procedures associated with device implantation, the number of patients at risk is growing too. If bacteremia develops, infected vegetation on the native/prosthetic valve or any intracardiac/intravascular device may occur as the final result of invading microorganisms/host immune system interaction. In the case of IE suspicion, all efforts must be focused on the diagnosis as IE can spread to almost any organ in the body. Unfortunately, the diagnosis of IE might be difficult and require a combination of clinical examination, microbiological assessment and echocardiographic evaluation. There is a need of novel microbiological and imaging techniques, especially in cases of blood culture-negative. In the last few years, the management of IE has changed. A multidisciplinary care team, including experts in infectious diseases, cardiology and cardiac surgery, namely, the Endocarditis Team, is highly recommended by the current guidelines.

Published
2023
Full Text
View/download PDF

26. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients

Author

Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, Giovanni Natale, Vittorio Patanè, Marco De Chiara, Mauro Buono, Gaetano Maria Russo, Riccardo Monti, Giovanni Balestrucci, Maria Salvarezza, Gaetano Di Guida, Emma D’Ippolito, Angelo Sangiovanni, Roberta Grassi, Ida D’Onofrio, Maria Paola Belfiore, Giovanni Cimmino, Carminia Maria Della Corte, Giovanni Vicidomini, Alfonso Fiorelli, Antonio Gambardella, Floriana Morgillo, Salvatore Cappabianca, Nardone, Valerio, Reginelli, Alfonso, De Marco, Giuseppina, Natale, Giovanni, Patanè, Vittorio, De Chiara, Marco, Buono, Mauro, Maria Russo, Gaetano, Monti, Riccardo, Balestrucci, Giovanni, Salvarezza, Maria, Di Guida, Gaetano, D’Ippolito, Emma, Sangiovanni, Angelo, Grassi, Roberta, D’Onofrio, Ida, Belfiore, Maria Paola, Cimmino, Giovanni, DELLA CORTE, Carminia Maria, Vicidomini, Giovanni, Fiorelli, Alfonso, Gambardella, Antonio, Morgillo, Floriana, and Cappabianca, Salvatore

Subjects
cardio-oncology, Clinical Biochemistry, biomarkers, heart, NSCLC, radiotherapy
Abstract

Treatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available in clinical practice. A novel and easy-to-calculate marker is the quantitative analysis of calcium plaque in the coronary, calculated on CT. It is called the Agatston score (or CAD score). At the same time, other potential predictors include cardiac ultrasonography and anamnesis of the patients. Our work aimed to correlate cardiac biomarkers with overall survival (OS) in NSCLC patients. We retrospectively analyzed patients with NSCLC discussed in the Multidisciplinary Tumor Board of our Institute for the present analysis between January 2018 and July 2022. Inclusion criteria were the availability of basal CT imaging of the thorax, cardiac ultrasonography with the calculation of ejection fraction (EF), and complete anamnesis, including assessment of co-pathologies and pharmacological drugs. The clinical data of the patients were retrospectively collected, and the CAD scores was calculated on a CT scan. All of these parameters were correlated with overall survival (OS) with univariate analysis (Kaplan–Meier analysis) and multivariate analysis (Cox regression analysis). Following the above-mentioned inclusion criteria, 173 patients were included in the present analysis. Of those, 120 patients died in the follow-up period (69.6%), and the median overall survival (OS) was 28 months (mean 47.2 months, 95% CI, 36–57 months). In univariate analysis, several parameters that significantly correlated with lower OS were the stage (p < 0.001), the CAD grading (p < 0.001), history of ischemic heart disease (p: 0.034), use of beta blocker drugs (p: 0.036), and cardiac ejection fraction (p: 0.005). In multivariate analysis, the only parameters that remained significant were as follows: CAD score (p: 0.014, OR 1.56, 95% CI: 1.04–1.83), stage (p: 0.016, OR: 1.26, 95% CI: 1.05–1.53), and cardiac ejection fraction (p: 0.011, OR 0.46, 95% CI: 0.25–0.84). Both CAD score and ejection fraction are correlated with survival in NSCLC patients at all stages of the disease. Independently from the treatment choice, a cardiological evaluation is mandatory for patients with NSCLC.

Published
2023
Full Text
View/download PDF

27. The Increasing Problem of Resistant Hypertension: We'll Manage till Help Comes!

Author

Natale F, Franzese R, Luisi E, Mollo N, Marotta L, Solimene A, D'Elia S, Golino P, and Cimmino G

Subjects
Humans, Drug Resistance, Hypertension drug therapy, Antihypertensive Agents therapeutic use
Abstract

Arterial hypertension remains the major cardiovascular risk worldwide. It is estimated that under 50 years of age one in every three adults is hypertensive while beyond the age of 50 the prevalence is almost 50% globally. The latest World Health Organization (WHO) Global Report on Hypertension indicated that the global number of hypertensive patients almost doubled in the last three decades, with related increasing deaths, disability, and costs annually. Because of this global increase, early diagnosis and timely treatment is of great importance. However, based on the WHO Global Report, it is estimated that up to 46% of individuals were never diagnosed. Of those diagnosed, less than 50% were on treatment, with nearly half among these at target according to the current guidelines. It is also important to note that an increasing number of hypertensive patients, despite the use of three or more drugs, still do not achieve a blood pressure normalization, thus defining the clinical scenario of resistant hypertension (RH). This condition is associated to a higher risk of hypertension-mediated organ damage and hospitalization due to acute cardiovascular events. Current guidelines recommend a triple combination therapy (renin angiotensin system blocking agent + a thiazide or thiazide-like diuretic + a dihydropyridinic calcium-channel blocker) to all patients with RH. Beta-blockers and mineralocorticoid receptor antagonists, alone or in combination, should be also considered based on concomitant conditions and potential contraindications. Finally, the renal denervation is also proposed in patients with preserved kidney function that remain hypertensive despite the use of maximum tolerated medical treatment. However, the failure of this procedure in the long term and the contraindication in patients with kidney failure is a strong call for a new therapeutic approach. In the present review, we will discuss the pharmacological novelties to come for the management of hypertension and RH in the next future.

Published
2024
Full Text
View/download PDF

28. Treating Aortic Valve Stenosis for Vitality Improvement: The TAVI Study.

Author

Tartaglione D, Prozzo D, Bianchi R, Ciccarelli G, Cappelli Bigazzi M, Natale F, Golino P, and Cimmino G

Abstract

Background: Degenerative aortic valve stenosis (AS) is the most common valvular heart disease among the elderly. Once cardiac symptoms occur, current guidelines recommend aortic valve replacement. Progressive degeneration/calcification reduces leaflet mobility with gradual cardiac output (CO) impairment. Low CO might induce abnormal brain-aging with cognitive impairment and increased risk of dementia, such as Alzheimer's disease or vascular dementia. On the contrary, cognitive improvement has been reported in patients in whom CO was restored. Transcatheter aortic valve implantation (TAVI) has proven to be a safe alternative to conventional surgery, with a similar mid-term survival and stroke risk even in low-risk patients. TAVI is associated with an immediate CO improvement, also effecting the cerebrovascular system, leading to an increased cerebral blood flow. The correlation between TAVI and cognitive improvement is still debated. The present study aims at evaluating this relationship in a cohort of AS patients where cognitive assessment before and after TAVI was available., Methods: a total of 47 patients were retrospectively selected. A transcranial Doppler ultrasound (TCD) before and after TAVI, a quality of life (QoL) score, as well as a mini-mental state examination (MMSE) at baseline and up to 36 months, were available., Results: TAVI was associated with immediate increase in mean cerebral flow at TCD. MMSE slowly increase at 36-months follow-up with improved QoL mainly for symptoms, emotions and social interactions., Conclusions: this proof-of-concept study indicates that TAVI might induce cognitive improvement in the long-term as a result of multiple factors, such as cerebral flow restoration and a better QoL.

Published
2024
Full Text
View/download PDF

29. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.

Author

Ciccarelli G, D'Elia S, De Paulis M, Golino P, and Cimmino G

Abstract

The role of low-density lipoproteins (LDLs) as a major risk factor for cardiovascular disease has been demonstrated by several epidemiological studies. The molecular basis for LDLs in atherosclerotic plaque formation and progression is not completely unraveled yet. Pharmacological modulation of plasma LDL-C concentrations and randomized clinical trials addressing the impact of lipid-lowering interventions on cardiovascular outcome have clearly shown that reducing plasma LDL-C concentrations results in a significant decrease in major cardiovascular events. For many years, statins have represented the most powerful pharmacological agents available to lower plasma LDL-C concentrations. In clinical trials, it has been shown that the greater the reduction in plasma LDL-C concentrations, the lower the rate of major cardiovascular events, especially in high-risk patients, because of multiple risk factors and recurrent events. However, in a substantial number of patients, the recommended LDL target is difficult to achieve because of different factors: genetic background (familial hypercholesterolemia), side effects (statin intolerance), or high baseline plasma LDL-C concentrations. In the last decade, our understanding of the molecular mechanisms involved in LDL metabolism has progressed significantly and the key role of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged. This protein is an enzyme able to bind the LDL receptors (LDL-R) on hepatocytes, favoring their degradation. Blocking PCSK9 represents an intriguing new therapeutic approach to decrease plasma LDL-C concentrations, which in recent studies has been demonstrated to also result in a significant reduction in major cardiovascular events., Competing Interests: The authors declare no conflict of interest.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results